Denislic M, Pirtosek Z, Vodusek D B, Zidar J, Meh D
University Institute of Clinical Neurophysiology Medical Center, Ljubljana, Slovenia.
Ann N Y Acad Sci. 1994 Mar 9;710:76-87. doi: 10.1111/j.1749-6632.1994.tb26615.x.
Botulinum toxin therapy is safe and effective in the treatment of different movement disorders, especially focal dystonias. We reviewed botulinum toxin treatment of 97 patients: 36 had blepharospasm, 41 had torticollis, and 20 had diverse movement disorders. Patients with blepharospasm and torticollis improved markedly after botulinum toxin injections. The most common side effect in BS patients was ptosis (44.4%); in TC patients, it was dysphagia (29.3%). The mean duration of the improvement in both groups was 3.4 months. Very promising results were obtained also in the heterogeneous group including patients with other focal dystonias and cerebral palsy. On the basis of these results, we concluded that BTA injections must now be considered the mainstay of therapy for focal dystonias and other involuntary movement disorders.
肉毒杆菌毒素疗法在治疗不同的运动障碍,尤其是局灶性肌张力障碍方面是安全有效的。我们回顾了97例接受肉毒杆菌毒素治疗的患者:36例患有眼睑痉挛,41例患有斜颈,20例患有多种运动障碍。眼睑痉挛和斜颈患者在注射肉毒杆菌毒素后明显改善。眼睑痉挛患者最常见的副作用是上睑下垂(44.4%);斜颈患者则是吞咽困难(29.3%)。两组改善的平均持续时间均为3.4个月。在包括其他局灶性肌张力障碍和脑瘫患者的异质性组中也获得了非常有前景的结果。基于这些结果,我们得出结论,现在必须将肉毒杆菌毒素A注射视为局灶性肌张力障碍和其他不自主运动障碍治疗的主要手段。